More than 600,000 bottles of prescription drugs used to treat high blood pressure and cholesterol are being recalled because the bottle caps are not child-resistant. The Consumer Product Safety ...
Please provide your email address to receive an email when new articles are posted on . Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of ...
Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020. The Food and Drug Administration (FDA) ...
Reduce elevated total-C and LDL-C in patients with homozygous familial; hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin; and Reduce elevated sitosterol and campesterol in ...
Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe) WHITEHOUSE STATION, N.J ...
NEW ORLEANS, November 8, 2004 – Results from a new study showed that coadministration of ZETIA® (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density ...
On April 24, 2009, Glenmark was granted tentative approval for its product by the U.S. Food and Drug Administration. Under the terms of the licensing and supply agreement, Par has made a payment to ...
Nexlizet (bempedoic acid and ezetimibe; Esperion) is now available for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results